What is the first-line treatment for chronic phase chronic myelogenous leukemia (CP-CML)?

Updated: Oct 23, 2019
  • Author: Rossa Khalaf, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


For the rare patient who is intolerant to those TIKIs, consider one of the following (note that bosutinib and ponatinib are approved for use only patients resistant to or intolerant to other therapies, not for first-line treatment):

For patients with intolerance to all TKIs , the following options can be alternatives:

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!